Shopping Cart
Remove All
Your shopping cart is currently empty
Monalizumab
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T76691 Copy Product Info
Purity: 95%
🥰Excellent
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
Cas No. 1228763-95-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $243 | In Stock | In Stock | |
| 5 mg | $786 | - | In Stock | |
| 10 mg | $1,280 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC). |
| In vitro | Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14. The results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor models[1]. |
| In vivo | Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14. The results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor models[1]. |
| Expression System | CHO |
| Endotoxin | <1.0 EU/mg |
| Reactivity | Human |
| Verified Activity | Human NKG2C/CD94-HEK293 cells at 1×10^5 cell/well can bind Monalizumab. |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | NKG2A/CD159a |
| Molecular Weight | 147 kDa |
| Cas No. | 1228763-95-8 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Keywords
Preview
Related Tags: Monalizumab chemical structure | Monalizumab in vivo | Monalizumab in vitro | Monalizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.